Investigating the miracle biologic Lecanemab for Alzheimer's Disease - Part 6

Lecanemab’s modified intention to treat analysis should come with a warning

Another issue that bothered us in the TTE office in the Lecanemab Early Alzheimer's Disease trial was the use of the modified intention-to-treat population for the efficacy analysis.

Internal validity of clinical trials is the extent to which you trust the methods on which the results are based. There are some simple methodological issues, such as the pr…